Cite

HARVARD Citation

    Dudnik, E. et al. (2021). Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. International journal of cancer. 148 (5), pp. 1183-1191. [Online]. 
  
Back to record